DNLI

Denali Therapeutics Inc. is a biopharmaceutical company developing therapies for neurodegenerative diseases. The company focuses on conditions including Alzheimer's disease, Parkinson's disease, ALS, and other diseases of the brain and nervous system. Denali's proprietary technology platforms include enzyme transport vehicles (ETV) for delivering therapeutics across the blood-brain barrier and other approaches targeting neurodegeneration. The company has multiple programs in clinical development and research collaborations with major pharmaceutical partners.